FDA under pressure for BPA safety
This article was originally published in The Tan Sheet
Executive Summary
Following a Sept. 17 study in the Journal of American Medical Association that finds higher concentrations of Bisphenol A in human urine is associated with cardiovascular disease, diabetes and liver-enzyme abnormalities, Reps. Rosa DeLauro, D-Conn., and John Dingell, D-Mich., criticize FDA's determination that BPA in food lining containers is safe. DeLauro says in a Sept. 16 release that FDA's stance on BPA's safety is "perplexing and dangerous." Likewise, Dingell urged the agency to "take careful notice of this new research during its Science Board meeting on Bisphenol A" Sept. 16, according to a same-day release. The most recent JAMA study does not conclusively link BPA in food containers as a cause of the associated diseases
You may also be interested in...
Science Board looks at BPA, contaminants
The FDA advisory group receives information on current methods for detecting contaminants in agency-regulated products and plans to discuss a subcommittee's review of bisphenol A use in food contact applications at an upcoming meeting. Although FDA has determined that BPA lining food containers is safe, a September study in the Journal of American Medical Association found higher concentrations of the substance in human urine is associated with cardiovascular disease, diabetes and liver-enzyme abnormalities (1"The Tan Sheet" Sept. 22, 2008, In Brief). In an Oct. 9 Federal Register notice, FDA says the board also will discuss its 2009 agenda topics during the meeting scheduled for Oct. 31 at the Washington, DC North/Gaithersburg Hilton in Gaithersburg, Md. The agency says background material on the topics should be available at least two days before the meeting
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.